

# 1<sup>ST</sup> INTERNATIONAL CONSENSUS CONFERENCE

Management of the  
Kidney Transplant  
Patient with Cancer  
Rome, 30 – 31 January 2020

Aula Brasca – Università Cattolica del Sacro Cuore  
Fondazione Policlinico Universitario A. Gemelli IRCCS

---

## Organising Committee (OC)

Jacopo Romagnoli  
Giovanni Scambia  
Giampaolo Tortora  
Vincenzo Valentini

## Scientific Committee (SC)

Jacopo Romagnoli (*Rome*) - *Scientific Coordinator*  
Anna Acampora (*Rome*) - *Methodological Coordinator*  
Stefan Hohaus (*Rome*)  
Roberto Iacovelli (*Rome*)  
Roberto Iezzi (*Rome*)  
Umberto Maggiore (*Parma*)

Ketty Peris (*Rome*)  
Ernesto Rossi (*Rome*)  
Giuseppe Scaletta (*Rome*)  
Giovanni Schinzari (*Rome*)  
Luca Tagliaferri (*Rome*)

## Work Group (WG) Members

Anna Acampora (*Rome*)  
Valentina Bianchi (*Rome*)  
Ilaria Esposito (*Rome*)  
Stefan Hohaus (*Rome*)  
Valentina Lancellotta (*Rome*)  
Elena Maiolo (*Rome*)

Filippo Paoletti (*Rome*)  
Alessandro Posa (*Rome*)  
Ernesto Rossi (*Rome*)  
Giuseppe Scaletta (*Rome*)  
Giovanni Schinzari (*Rome*)  
Gionata Spagnoletti (*Rome*)

## Invited Speakers

Luigi Biancone (*Turin*)  
Vincenzo Cantaluppi (*Novara*)  
Valeriana Colombo (*Milan*)  
Laura Cosmai (*Milano*)  
Alessandro Di Stefani (*Rome*)  
Paola Donato (*Verona*)  
Lucrezia Furian (*Padua*)  
Maria Antonietta Gambacorta (*Rome*)  
Giuseppe Grandaliano (*Rome*)  
Rosario Francesco Grasso (*Rome*)  
Barbara Jereczek Fossa (*Milan*)  
György Kovács (*Lübeck*)

Mario Luppi (*Modena*)  
Umberto Maggiore (*Parma*)  
Nizam Mamode (*London*)  
Alessandra Palmisano (*Parma*)  
Camillo Porta (*Pavia*)  
Daniele Santini (*Rome*)  
Søren Schwartz Sorensen (*Copenhagen*)  
Giovanni Stallone (*Foggia*)  
Andrea Veltri (*Turin*)  
Fabio Vistoli (*Pisa*)  
Bruno Watschinger (*Vienna*)

---

**PRELIMINARY PROGRAMME**

Thursday, 30 January 2020

14:15 – 14:45                    **OPENING CEREMONY**

14:45 – 15:00                    **PRESENTATION OF THE CONFERENCE METHODOLOGY**

Jacopo Romagnoli (Rome)

15:00 – 18:00                    **Session I**

**INTEGRATED THERAPY**

Moderators: **Vincenzo Valentini** (Rome), **Riccardo Manfredi** (Rome)

15:00 – 15:40

***Does withdrawing antimetabolites and/or CNI inhibitors and/or mTOR-inhibitors as opposed to continuing maintenance immunosuppression improve patient survival in kidney transplant recipients with cancer undergoing radiotherapy? Q5***

Presenter: **Luca Tagliaferri** (Rome)

- 1<sup>st</sup> discussant: **Valeriana Colombo** (Milan)
- 2<sup>nd</sup> discussant: **Barabara Jereczek Fossa** (Milan)
- Discussion and voting

15:40 – 16:20

***Should a kidney transplant patient with cancer avoid standard radiotherapy technique (EBRT, BT, SBRT, protons), dose and volume in order to preserve the transplanted kidney? Q9***

Presenter: **Valentina Lancellotta** (Rome)

- 1<sup>st</sup> discussant: **Vincenzo Cantaluppi** (Novara)
- 2<sup>nd</sup> discussant: **Maria Antonietta Gambacorta** (Rome)
- Discussion and voting

16:20 – 16:40

Coffee break

16:40 – 17:20

***In case of cancer of the transplanted kidney, is focal treatment (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation, stereobody radiotherapy, protons) indicated as the standard treatment as opposed to graft nephrectomy? Q10***

Presenter: **Alessandro Posa** (Rome)

- 1<sup>st</sup> discussant: **Lucrezia Furian** (Padua)
- 2<sup>nd</sup> discussant: **Rosario Francesco Grasso** (Rome)
- Discussion and voting

17:20 – 18:00

***In case of focal treatment, is percutaneous approach (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation) indicated as the standard treatment as opposed to external beam radiotherapy (stereobody radiotherapy, protons)? Q11***

Presenter: **Roberto Iezzi** (Rome)

- 1<sup>st</sup> discussant: **György Kovács** (Lübeck, Germany)
- 2<sup>nd</sup> discussant: **Andrea Veltri** (Turin)
- Discussion and voting

18:00 – 18:10

**CONCLUSIONS**

Jacopo Romagnoli (Rome)

Friday, 31 January 2020

- 08:45 – 09:00**                    **PRESENTATION OF THE CONFERENCE METHODOLOGY**  
Jacopo Romagnoli (*Rome*)
- 09:00 – 11:00**                    **Session IIa**  
**IMMUNOSUPPRESSIVE THERAPY**  
Moderators: **Franco Citterio** (*Rome*), **Umberto Maggiore** (*Parma*)
- 09:00 – 09:40                    ***Should immunosuppression be stopped or modified before oncological surgery in the kidney transplant recipient? Q12***
- Presenter: **Giuseppe Scaletta** (*Rome*)
- 1<sup>st</sup> discussant: **Nizam Mamode** (*London, UK*)
  - 2<sup>nd</sup> discussant: **Fabio Vistoli** (*Pisa*)
  - Discussion and voting
- 09:40 – 10:20                    ***Does maintaining as opposed to withdrawing or reducing calcineurin inhibitors in kidney transplant recipients with non-metastatic, non-skin cancer undergoing chemotherapy worsen patient or graft survival? Q3***
- Presenter: **Valentina Bianchi** (*Rome*)
- 1<sup>st</sup> discussant: **Bruno Watschinger** (*Vienna, Austria*)
  - 2<sup>nd</sup> discussant: **Laura Cosmai** (*Milan*)
  - Discussion and voting
- 10:20 – 11:00                    ***Does the switch from calcineurin inhibitors to mTOR-inhibitors improve patient or graft survival of kidney transplant recipients with metastatic non-skin cancer undergoing chemotherapy? Q1***
- Presenter: **Gionata Spagnoletti** (*Rome*)
- 1<sup>st</sup> discussant: **Søren Schwartz Sørensen** (*Copenhagen, Denmark*)
  - 2<sup>o</sup> discussant: **Laura Cosmai** (*Milan*)
  - Discussion and voting
- 11:00 – 11:20                    Coffee Break
- 11:20 – 12:40**                    **Session IIb**  
**IMMUNOSUPPRESSIVE THERAPY AND IMMUNOTHERAPY**  
Moderators: **Giuseppe Grandaliano** (*Rome*), **Ketty Peris** (*Rome*)
- 11:20 – 12:00                    ***Does maintaining as opposed to withdrawing calcineurin inhibitors in kidney transplant recipients with PTLN, undergoing first-line chemotherapy worsen patient or graft survival? Q2***
- Presenter: **Stefan Hohaus** (*Rome*)
- 1<sup>st</sup> discussant: **Paola Donato** (*Verona*)
  - 2<sup>nd</sup> discussant: **Mario Luppi** (*Modena*)
  - Discussion and voting

- 12:00 – 12:40 **Does the use of checkpoint inhibitors in kidney transplant recipients with metastatic skin and non-skin cancer have a negative impact on patient or graft survival? Q4**
- Presenter: **Ernesto Rossi / Ilaria Esposito** (Rome)
- 1st discussant: **Alessandra Palmisano** (Parma)
  - 2nd discussant: **Alessandro Di Stefani** (Rome)
  - 3rd discussant: **Daniele Santini** (Rome)
  - Discussion and voting
- 12:40 – 13:00 Lectio Magistralis  
**HOW TO DEAL WITH A SURGICAL CRISIS**  
**Nizam Mamode** (London, UK)
- 13:00 – 14:00 Lunch
- 14:00 – 17:00** **Session III**  
**CHEMOTHERAPY**  
Moderators: **Giampaolo Tortora** (Rome), **Mario Luppi** (Modena)
- 14:00 – 14:40 **Can anti-angiogenic drugs be safely used in kidney transplant recipients with cancer? Q6**
- Presenter: **Ernesto Rossi** (Rome)
- 1<sup>st</sup> discussant: **Giuseppe Grandaliano** (Rome)
  - 2<sup>nd</sup> discussant: **Camillo Porta** (Pavia)
  - Discussion and voting
- 14:40 – 15:20 **Can hormone therapy be safely used in kidney transplant recipients with cancer? Q7**
- Presenter: **Filippo Paoletti** (Rome)
- 1<sup>st</sup> discussant: **Giovanni Stallone** (Foggia)
  - 2<sup>nd</sup> discussant: **Daniele Santini** (Rome)
  - Discussion and voting
- 15:20 – 16:00 **Can platinum salts be safely used in kidney transplant recipients with cancer? Q8**
- Presenter: **Giovanni Schinzari** (Rome)
- 1<sup>st</sup> discussant: **Luigi Biancone** (Turin)
  - 2<sup>nd</sup> discussant: **Camillo Porta** (Pavia)
  - Discussion and voting
- 16:00 – 16:20 Coffee Break
- 16:20 – 17:00 **Summary and Conclusions**  
**Jacopo Romagnoli** (Rome)